Showing results (31-40 of 56) with videos related to

Sort By:
Pageof 6
BMC Infectious Diseases|December 8, 2021
Provider perspectives on the acceptability and tolerability of dolutegravir-based anti-retroviral therapy after national roll-out in Uganda: a qualitative studyHenry Zakumumpa, Freddy Eric Kitutu, Helen Byomire Ndagije, et al.
Research Square|July 28, 2023
Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adultsFrank Mulindwa, Barbara Castelnuovo, Nele Brusselaers, et al.
Antibiotics (Basel, Switzerland)|July 29, 2020
Prescription of Levofloxacin and Moxifloxacin in Select Hospitals in Uganda: A Pilot Study to Assess Guideline ConcordanceVictoria Nambasa, Helen B Ndagije, Allan Serwanga, et al.
Drug Safety|April 25, 2023
Facilitators and Barriers to Uptake of the Med Safety Mobile App for Adverse Drug Reaction Reporting by Health Workers in Uganda: A Qualitative StudyRonald Kiguba, Henry Zakumumpa, Helen B Ndagije, et al.
BMJ Open|April 29, 2024
Navigating duplication in pharmacovigilance databases: a scoping reviewRonald Kiguba, Gerald Isabirye, Julius Mayengo, et al.
Malaria Journal|November 4, 2020
Pharmacovigilance of suspected or confirmed therapeutic ineffectiveness of artemisinin-based combination therapy: extent, associated factors, challenges and solutions to reportingRonald Kiguba, Helen Byomire Ndagije, Victoria Nambasa, et al.
OTO Open|July 7, 2022
Smell and Taste Symptoms Among Patients With Mild and Moderately Severe COVID-19 Infection in UgandaRichard Byaruhanga, Fiona Kabagenyi, Douglas Ssenyonjo Kagga, et al.
Plos One|August 1, 2025
CYP2B6*6 single nucleotide polymorphism among patients with uncomplicated malaria in Adjumani district, Uganda: Implications on efficacy of artemether-lumefantrineMartin Kamilo Angwe, Norah Mwebaza, Sam Lubwama Nsobya, et al.
Medrxiv : the Preprint Server for Health Sciences|June 30, 2025
<i>CYP2B6*6</i> single nucleotide polymorphism among patients with uncomplicated malaria in Adjumani district, Uganda: implications on efficacy of artemether-lumefantrineMartin Kamilo Angwe, Norah Mwebaza, Sam Lubwama Nsobya, et al.
AIDS Research and Therapy|September 9, 2023
Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adultsFrank Mulindwa, Barbara Castelnuovo, Nele Brusselaers, et al.
Pageof 6